Dow BioMedica to distribute Biohit GastroPanel® in Korea
Biohit Oyj Press release, 15[th] February, 2018 at 9.30 a.m. local time (EET) Biohit Oyj and Dow BioMedica have signed an agreement for the distribution of Biohit GastroPanel in Korea. The contract has been signed for four years with a continuation option. The registration will start during the 1[st] quarter of 2018. CEO Young Gill Shin, Dow BioMedica Inc.: “Korea has high incidence of Helicobacter pylori infection caused atrophic gastritis and related risks such as gastric cancer. GastroPanel as a primary examination will find patients for further examination, and allows more cost-